NASDAQ:FWAA

Fifth Wall Acquisition Corp. I Competitors

Notice: Trading of Fifth Wall Acquisition Corp. I halted at 07:55 AM EST due to "News pending".
$10.23
0.00 (0.00 %)
(As of 04/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.09
Now: $10.23
$10.26
50-Day Range
$9.94
MA: $10.23
$10.80
52-Week Range
$9.77
Now: $10.23
$11.67
Volume17,459 shs
Average Volume194,525 shs
Market Capitalization$393.43 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Fifth Wall Acquisition Corp. I (NASDAQ:FWAA) Vs. APR, DSGN, TBA, BVS, ADAG, and IKNA

Should you be buying FWAA stock or one of its competitors? Companies in the industry of "--" are considered alternatives and competitors to Fifth Wall Acquisition Corp. I, including Apria (APR), Design Therapeutics (DSGN), Thoma Bravo Advantage (TBA), Bioventus (BVS), Adagene (ADAG), and Ikena Oncology (IKNA).

Fifth Wall Acquisition Corp. I (NASDAQ:FWAA) and Apria (NYSE:APR) are both small-cap -- companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Profitability

This table compares Fifth Wall Acquisition Corp. I and Apria's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fifth Wall Acquisition Corp. IN/AN/AN/A
ApriaN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Fifth Wall Acquisition Corp. I and Apria, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fifth Wall Acquisition Corp. I0000N/A
Apria00503.00

Apria has a consensus price target of $29.20, indicating a potential downside of 3.73%. Given Apria's higher probable upside, analysts plainly believe Apria is more favorable than Fifth Wall Acquisition Corp. I.

Valuation and Earnings

This table compares Fifth Wall Acquisition Corp. I and Apria's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fifth Wall Acquisition Corp. IN/AN/AN/AN/AN/A
ApriaN/AN/AN/AN/AN/A

Summary

Apria beats Fifth Wall Acquisition Corp. I on 2 of the 2 factors compared between the two stocks.

Fifth Wall Acquisition Corp. I (NASDAQ:FWAA) and Design Therapeutics (NASDAQ:DSGN) are both small-cap -- companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Valuation and Earnings

This table compares Fifth Wall Acquisition Corp. I and Design Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fifth Wall Acquisition Corp. IN/AN/AN/AN/AN/A
Design TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Fifth Wall Acquisition Corp. I and Design Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fifth Wall Acquisition Corp. I0000N/A
Design Therapeutics01202.67

Design Therapeutics has a consensus price target of $35.3333, indicating a potential upside of 80.73%. Given Design Therapeutics' higher probable upside, analysts plainly believe Design Therapeutics is more favorable than Fifth Wall Acquisition Corp. I.

Profitability

This table compares Fifth Wall Acquisition Corp. I and Design Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fifth Wall Acquisition Corp. IN/AN/AN/A
Design TherapeuticsN/AN/AN/A

Summary

Design Therapeutics beats Fifth Wall Acquisition Corp. I on 2 of the 2 factors compared between the two stocks.

Thoma Bravo Advantage (NYSE:TBA) and Fifth Wall Acquisition Corp. I (NASDAQ:FWAA) are both small-cap -- companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.

Profitability

This table compares Thoma Bravo Advantage and Fifth Wall Acquisition Corp. I's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Thoma Bravo AdvantageN/AN/AN/A
Fifth Wall Acquisition Corp. IN/AN/AN/A

Earnings & Valuation

This table compares Thoma Bravo Advantage and Fifth Wall Acquisition Corp. I's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thoma Bravo AdvantageN/AN/AN/AN/AN/A
Fifth Wall Acquisition Corp. IN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for Thoma Bravo Advantage and Fifth Wall Acquisition Corp. I, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Thoma Bravo Advantage0000N/A
Fifth Wall Acquisition Corp. I0000N/A

Bioventus (NYSE:BVS) and Fifth Wall Acquisition Corp. I (NASDAQ:FWAA) are both small-cap -- companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.

Earnings and Valuation

This table compares Bioventus and Fifth Wall Acquisition Corp. I's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioventusN/AN/AN/AN/AN/A
Fifth Wall Acquisition Corp. IN/AN/AN/AN/AN/A

Profitability

This table compares Bioventus and Fifth Wall Acquisition Corp. I's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioventusN/AN/AN/A
Fifth Wall Acquisition Corp. IN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Bioventus and Fifth Wall Acquisition Corp. I, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bioventus00403.00
Fifth Wall Acquisition Corp. I0000N/A

Bioventus currently has a consensus target price of $19.50, indicating a potential upside of 32.29%. Given Bioventus' higher possible upside, research analysts plainly believe Bioventus is more favorable than Fifth Wall Acquisition Corp. I.

Summary

Bioventus beats Fifth Wall Acquisition Corp. I on 2 of the 2 factors compared between the two stocks.

Fifth Wall Acquisition Corp. I (NASDAQ:FWAA) and Adagene (NASDAQ:ADAG) are both small-cap -- companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Profitability

This table compares Fifth Wall Acquisition Corp. I and Adagene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fifth Wall Acquisition Corp. IN/AN/AN/A
AdageneN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and recommmendations for Fifth Wall Acquisition Corp. I and Adagene, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fifth Wall Acquisition Corp. I0000N/A
Adagene00303.00

Adagene has a consensus target price of $32.00, suggesting a potential upside of 107.79%. Given Adagene's higher probable upside, analysts plainly believe Adagene is more favorable than Fifth Wall Acquisition Corp. I.

Valuation & Earnings

This table compares Fifth Wall Acquisition Corp. I and Adagene's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fifth Wall Acquisition Corp. IN/AN/AN/AN/AN/A
AdageneN/AN/AN/AN/AN/A

Summary

Adagene beats Fifth Wall Acquisition Corp. I on 2 of the 2 factors compared between the two stocks.

Ikena Oncology (NASDAQ:IKNA) and Fifth Wall Acquisition Corp. I (NASDAQ:FWAA) are both small-cap -- companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Profitability

This table compares Ikena Oncology and Fifth Wall Acquisition Corp. I's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ikena OncologyN/AN/AN/A
Fifth Wall Acquisition Corp. IN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations for Ikena Oncology and Fifth Wall Acquisition Corp. I, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ikena Oncology00303.00
Fifth Wall Acquisition Corp. I0000N/A

Ikena Oncology presently has a consensus target price of $30.00, suggesting a potential upside of 55.93%. Given Ikena Oncology's higher probable upside, research analysts clearly believe Ikena Oncology is more favorable than Fifth Wall Acquisition Corp. I.

Valuation and Earnings

This table compares Ikena Oncology and Fifth Wall Acquisition Corp. I's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ikena OncologyN/AN/AN/AN/AN/A
Fifth Wall Acquisition Corp. IN/AN/AN/AN/AN/A

Summary

Ikena Oncology beats Fifth Wall Acquisition Corp. I on 2 of the 2 factors compared between the two stocks.


Fifth Wall Acquisition Corp. I Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Apria logo
APR
Apria
1.4$30.33flat$1.07 billionN/A0.00
DSGN
Design Therapeutics
1.3$19.55flat$1.05 billionN/A0.00Analyst Report
Analyst Revision
TBA
Thoma Bravo Advantage
0.0$10.02flat$1.03 billionN/A0.00
Bioventus logo
BVS
Bioventus
2.0$14.74flat$837.60 millionN/A0.00Analyst Report
Adagene logo
ADAG
Adagene
1.7$15.40flat$666.56 millionN/A0.00
IKNA
Ikena Oncology
1.7$19.24flat$665.47 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
CCV
Churchill Capital Corp V
0.0$10.19flat$636.88 millionN/A0.00
CTOS
Custom Truck One Source
1.5$9.95flat$487.89 millionN/A0.00News Coverage
SVFC
SVF Investment Corp. 3
0.3$10.29flat$370.03 millionN/A0.00Quiet Period Expiration
UTME
United Time Technology
0.0$38.20flat$315.84 millionN/A0.00
LVTX
Lava Therapeutics B.V.
1.7$12.30flat$311.83 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
SVFB
SVF Investment Corp. 2
0.3$10.23flat$262.91 millionN/A0.00Quiet Period Expiration
VHAQ
Viveon Health Acquisition
0.0$9.91flat$249.30 millionN/A0.00
WNW
Wunong Net Technology
0.0$8.72flat$218 millionN/A0.00
LBPS
4D pharma
1.0$12.61flat$207.22 millionN/A0.00Upcoming Earnings
Gap Up
HCAQ
HealthCor Catalio Acquisition
0.0$9.93flat$205.55 millionN/A0.00
RACB
Research Alliance Corp. II
0.0$11.00flat$183.81 millionN/A0.00Quiet Period Expiration
ARYD
ARYA Sciences Acquisition Corp IV
0.0$10.85flat$181.30 millionN/A0.00
ABGI
ABG Acquisition Corp. I
0.0$9.98flat$168.03 millionN/A0.00
PLBY Group logo
PLBY
PLBY Group
1.1$45.14flat$166.16 millionN/A0.00High Trading Volume
Biophytis logo
BPTS
Biophytis
0.0$13.00flat$147.07 millionN/A0.00Gap Down
Vivos Therapeutics logo
VVOS
Vivos Therapeutics
1.3$8.00flat$145.70 millionN/A0.00Analyst Upgrade
MRAC
Marquee Raine Acquisition
0.0$9.84flat$108.25 millionN/A0.00
EEIQ
Elite Education Group International
0.0$5.42flat$47.70 millionN/A0.00Gap Up
Presidio Property Trust logo
SQFT
Presidio Property Trust
0.3$3.19flat$31.57 millionN/A0.00
IGNY
Ignyte Acquisition
0.0$9.81flat$19.03 millionN/A0.00
AFAQU
AF Acquisition
0.0$10.00flat$0.00N/A0.00
ANZUU
Anzu Special Acquisition Corp I
0.0$9.95flat$0.00N/A0.00
ATSPU
Archimedes Tech SPAC Partners
0.0$9.96flat$0.00N/A0.00Quiet Period Expiration
ARRWU
Arrowroot Acquisition
0.0$9.99flat$0.00N/A0.00News Coverage
AUUD
Auddia
0.0$2.33flat$0.00N/A0.00
BSA
BrightSphere Investment Group
0.0$25.37flat$0.00N/A0.00
CPZ
Calamos Long/Short Equity & Dynamic Income Term Trust
0.0$20.12flat$0.00N/A0.00
CMLTU
CM Life Sciences III
0.0$10.94flat$0.00N/A0.00
CRZNU
Corazon Capital V838 Monoceros
0.0$10.03flat$0.00N/A0.00High Trading Volume
DCRCU
Decarbonization Plus Acquisition Corp III
0.0$10.01flat$0.00N/A0.00
DLY
DoubleLine Yield Opportunities Fund
0.0$19.56flat$0.00N/A0.00
EBACU
European Biotech Acquisition
0.0$10.06flat$0.00N/A0.00Quiet Period Expiration
EVOJ
Evo Acquisition
0.3$9.75flat$0.00N/A0.00
FRSGU
First Reserve Sustainable Growth
0.0$10.02flat$0.00N/A0.00News Coverage
FMIVU
Forum Merger IV
0.0$10.00flat$0.00N/A0.00Quiet Period Expiration
FRONU
Frontier Acquisition
0.0$10.18flat$0.00N/A0.00Quiet Period Expiration
HERAU
FTAC Hera Acquisition
0.0$10.01flat$0.00N/A0.00
GLHAU
Glass Houses Acquisition
0.0$10.00flat$0.00N/A0.00
GLSPU
Global SPAC Partners
0.0$10.00flat$0.00N/A0.00
GMLPP
Golar LNG Partners LP 8.75% CUM PFD A
0.8$25.75flat$0.00N/A0.00
GAMCU
Golden Arrow Merger
0.0$9.99flat$0.00N/A0.00Quiet Period Expiration
GBRGU
Goldenbridge Acquisition
0.0$10.39flat$0.00N/A0.00
GSEVU
Gores Holdings VII
0.0$10.03flat$0.00N/A0.00
HGLB
Highland Global Allocation Fund
0.3$9.04flat$0.00N/A0.00
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected]rketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.